Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 10/20 | 0.58 |
| ▸ | CHUK | O15111 | 7/20 | 0.43 |
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16205642 | 0.96 | MAP3K14 (0.54) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205446 | 0.94 | MAP3K14 (0.53) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205627 | 0.93 | MAP3K14 (0.59) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205536 | 0.92 | MAP3K14 (0.61) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205515 | 0.92 | MAP3K14 (0.64) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205531 | 0.91 | MAP3K14 (0.60) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205647 | 0.90 | MAP3K14 (0.57) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205537 | 0.90 | MAP3K14 (0.62) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205634 | 0.90 | MAP3K14 (0.56) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205639 | 0.89 | MAP3K14 (0.60) | MAP3K14CHUKTTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3209662-B1 | NEW COMPOUNDS AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| US-10005776-B2 | Compounds as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-10005776-B2 | Compounds as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-20170334906-A1 | NEW COMPOUNDS AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-20170334906-A1 | NEW COMPOUNDS AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005776-B2 | Compounds as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | MAP3K14 1/4885CHUK 24/4885TTBK1 536/4885 |
| US-20170334906-A1 | NEW COMPOUNDS AS NIK INHIBITORS | MAP3K14, IKBKG, MAP3K15 | MAP3K14 1/4885CHUK 24/4885TTBK1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.